참고문헌 (69)

1. Expert Rev. Anticancer Ther. Alex 20 11 931 2020 10.1080/14737140.2020.1816173 Promising predictors of checkpoint inhibitor response in NSCLC 

   상세보기

2. J. Exp. Clin. Cancer Res. Allegretti 37 1 47 2018 10.1186/s13046-018-0702-x Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations 

   상세보기

3. N. Engl. J. Med. André 383 23 2207 2020 10.1056/NEJMoa2017699 Pembrolizumab in microsatellite-instability-High advanced colorectal Cancer 

   상세보기

4. Lancet Balar 389 10064 67 2017 10.1016/S0140-6736(16)32455-2 Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial 

   상세보기

5. Front. Med. (Lausanne) Banna 6 172 2019 The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy 

6. Clin. Transl. Oncol. Banna 22 11 2130 2020 10.1007/s12094-020-02337-3 Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy 

   상세보기

7. ESMO Open Banna 6 2 2021 10.1016/j.esmoop.2021.100078 The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 

   상세보기

8. N. Engl. J. Med. Bellmunt 376 11 1015 2017 10.1056/NEJMoa1613683 Pembrolizumab as second-line therapy for advanced urothelial carcinoma 

   상세보기

9. Oncoimmunology Boichard 6 3 2017 10.1080/2162402X.2017.1284719 High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations 

   상세보기

10. Oncoimmunology Boichard 8 3 2019 10.1080/2162402X.2018.1550341 APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy 

    상세보기

11. Gastroenterology Boland 138 6 2073 2010 10.1053/j.gastro.2009.12.064 Microsatellite instability in colorectal Cancer 

    상세보기

12. Am. J. Clin. Oncol. Buchbinder 39 1 98 2016 10.1097/COC.0000000000000239 CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition 

    상세보기

13. ESMO Open Büttner 4 1 2019 10.1136/esmoopen-2018-000442 Implementing TMB measurement in clinical practice: considerations on assay requirements 

    상세보기

14. Oncotarget Campesato 6 33 34221 2015 10.18632/oncotarget.5950 Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice 

    상세보기

15. Clin. Cancer Res. Chabanon 22 17 4309 2016 10.1158/1078-0432.CCR-16-0903 Mutational landscape and sensitivity to immune checkpoint blockers 

    상세보기

16. Genome Med. Chalmers 9 1 1 2017 10.1186/s13073-017-0424-2 Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden 

    상세보기

17. Am. Soc. Clin. Oncol. Davis 2017 10.1200/JCO.2017.35.15_suppl.e23028 Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA) 

    상세보기

18. J. Clin. Oncol. Devarakonda 36 30 2995 2018 10.1200/JCO.2018.78.1963 Tumor mutation burden as a biomarker in resected non-small-cell lung cancer 

    상세보기

19. Appl. Transl. Genom. Endrullat 10 2 2016 Standardization and quality management in next-generation sequencing 

20. Ann. Oncol. Fabrizio 28 v27 2017 10.1093/annonc/mdx363.018 Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) 

    상세보기

21. J. Immunother. Cancer Fancello 7 1 1 2019 10.1186/s40425-019-0647-4 Tumor mutational burden quantification from targeted gene panels: major advancements and challenges 

    상세보기

22. JAMA Oncol. Ferrara 4 11 1543 2018 10.1001/jamaoncol.2018.3676 Hyperprogressive disease in patients with advanced non-Small cell lung Cancer Treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy 

    상세보기

23. Food 2020 Highlights of Prescribing Information: Keytruda 

24. Food, U., Administration, D 2020 FDA Approves Pembrolizumab for Adults and Children With TMB-H Solid Tumors 

25. Lung Cancer Manag. Friedlaender 8 3 2019 10.2217/lmt-2019-0009 Identifying successful biomarkers for patients with non-small-cell lung cancer 

    상세보기

26. Nat. Med. Gandara 24 9 1441 2018 10.1038/s41591-018-0134-3 Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab 

    상세보기

27. Nat. Biotechnol. Gargis 30 11 1033 2012 10.1038/nbt.2403 Assuring the quality of next-generation sequencing in clinical laboratory practice 

    상세보기

28. Genome Med. Garofalo 8 1 79 2016 10.1186/s13073-016-0333-9 The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine 

    상세보기

29. Mol. Cancer Ther. Goodman 16 11 2598 2017 10.1158/1535-7163.MCT-17-0386 Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers 

    상세보기

30. JAMA Oncol. Goodman 4 9 1237 2018 10.1001/jamaoncol.2018.1701 Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors 

    상세보기

31. Cancer Immunol. Res. Goodman 7 10 1570 2019 10.1158/2326-6066.CIR-19-0149 Microsatellite-stable tumors with high mutational burden benefit from immunotherapy 

    상세보기

32. Cancer Cell Hellmann 33 5 2018 10.1016/j.ccell.2018.03.018 Genomic features of response to combination immunotherapy in patients with advanced non-small-Cell lung Cancer 

    상세보기

33. Cancer Immunol. Res. Johnson 4 11 959 2016 10.1158/2326-6066.CIR-16-0143 Targeted next generation sequencing identifies markers of response to PD-1 blockade 

    상세보기

34. Nat. Commun. Kanchi 5 2014 10.1038/ncomms4156 Integrated analysis of germline and somatic variants in ovarian cancer 

    상세보기

35. Sci. Rep. Kaur 9 1 1482 2019 10.1038/s41598-018-37574-8 Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer 

    상세보기

36. Clin. Cancer Res. Khagi 23 19 5729 2017 10.1158/1078-0432.CCR-17-1439 Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy 

    상세보기

37. Nucleic Acids Res. Kircher 40 1 2011 10.1093/nar/gkr771 Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform 

    상세보기

38. Klute 2020 Cobimetinib Plus Vemurafenib (C+ V) in Patients (Pts) With Colorectal Cancer (CRC) With BRAF V600E Mutations: Results From the TAPUR Study 

39. Mol. Diagn. Ther. Kotrova 21 5 481 2017 10.1007/s40291-017-0277-9 Is next-generation sequencing the way to go for residual disease monitoring in acute lymphoblastic leukemia? 

    상세보기

40. Cancer Cell Int. Li 20 2020 Microsatellite instability: a review of what the oncologist should know 

    상세보기

41. N. Engl. J. Med. Lynch 348 10 919 2003 10.1056/NEJMra012242 Hereditary colorectal Cancer 

    상세보기

42. Ann. Oncol. Marinelli 31 12 1746 2020 10.1016/j.annonc.2020.08.2105 KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 

    상세보기

43. Nature Matsushita 482 7385 400 2012 10.1038/nature10755 Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting 

    상세보기

44. Ann. Oncol. McGrail 32 5 661 2021 10.1016/j.annonc.2021.02.006 High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types 

    상세보기

45. Cancer Res. Mola 78 13 Supplement 2018 Abstract 2250: tumor mutational burden: guidelines for derivation and robustness of measurement 

46. J. Thorac. Oncol. Müller 12 10 1503 2017 10.1016/j.jtho.2017.07.014 Concordance between comprehensive cancer genome profiling in plasma and tumor specimens 

    상세보기

47. PLoS One Nelson 9 4 2014 10.1371/journal.pone.0094249 Analysis, optimization and verification of Illumina-generated 16S rRNA gene amplicon surveys 

    상세보기

48. Gene Expr. Onuma 20 1 53 2020 10.3727/105221620X15880179864121 Immune checkpoint inhibitors in hepatocellular cancer: current understanding on mechanisms of resistance and biomarkers of response to treatment 

    상세보기

49. Mol. Cancer Ther. Patel 14 4 847 2015 10.1158/1535-7163.MCT-14-0983 PD-L1 expression as a predictive biomarker in cancer immunotherapy 

    상세보기

50. No. Annals of oncology : official journal of the European Society for Medical Oncology. Prasad 2020 10.1016/j.annonc.2020.07.001 The FDA approval of pembrolizumab for patients with TMB &10 mut/Mb: was it a wise decision? 

    상세보기

51. N. Engl. J. Med. Reck 375 19 1823 2016 10.1056/NEJMoa1606774 Pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung Cancer 

    상세보기

52. Eur. J. Cancer Reck 116 137 2019 10.1016/j.ejca.2019.05.008 Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial 

    상세보기

53. Mol. Cell Reuter 58 4 586 2015 10.1016/j.molcel.2015.05.004 High-throughput sequencing technologies 

    상세보기

54. Cancers Rossi 12 5 1125 2020 10.3390/cancers12051125 Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient 

    상세보기

55. N. Engl. J. Med. Rousseau 384 12 1168 2021 10.1056/NEJMc2031965 The Spectrum of benefit from checkpoint blockade in hypermutated tumors 

    상세보기

56. Nat. Genet. Samstein 51 2 202 2019 10.1038/s41588-018-0312-8 Tumor mutational load predicts survival after immunotherapy across multiple cancer types 

    상세보기

57. Annu. Rev. Immunol. Schumacher 37 173 2019 10.1146/annurev-immunol-042617-053402 Cancer neoantigens 

    상세보기

58. Genet. Med. Schwarze 20 10 1122 2018 10.1038/gim.2017.247 Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature 

    상세보기

59. Lancet Oncol. Seiwert 17 7 956 2016 10.1016/S1470-2045(16)30066-3 Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial 

    상세보기

60. Ann. Oncol. Siravegna 30 10 1580 2019 10.1093/annonc/mdz227 How liquid biopsies can change clinical practice in oncology 

    상세보기

61. Nat. Rev. Cancer Skoulidis 19 9 495 2019 10.1038/s41568-019-0179-8 Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy 

    상세보기

62. N. Engl. J. Med. Snyder 371 23 2189 2014 10.1056/NEJMoa1406498 Genetic basis for clinical response to CTLA-4 blockade in melanoma 

    상세보기

63. Ann. Oncol. Subbiah 2020 10.1016/j.annonc.2020.07.002 The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians 

    상세보기

64. Lancet Oncol. Turajlic 18 8 1009 2017 10.1016/S1470-2045(17)30516-8 Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis 

    상세보기

65. Nat. Commun. Valero 12 1 729 2021 10.1038/s41467-021-20935-9 Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors 

    상세보기

66. JCO Precis Oncol Vokes 3 1 2019 Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer 

    상세보기

67. Genome Med. Wood 12 1 2020 10.1186/s13073-020-00729-2 Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival 

    상세보기

68. Ann. Transl. Med. Wu 7 22 2019 10.21037/atm.2019.10.116 Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers 

    상세보기

69. Nat. Med. Zehir 23 6 703 2017 10.1038/nm.4333 Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients 

    상세보기